Ascendis Pharma A (ASND) Common Equity (2012 - 2026)

Ascendis Pharma A has disclosed Common Equity across 15 years of filings, most recently posting $571.3 million for Q1 2026.

• Common Equity for Q1 2026 came in at $571.3 million, up 386.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $571.3 million (up 386.14% YoY), and the FY2025 annual result was -$189.5 million, down 107.41% from the prior year.
• Common Equity came in at $571.3 million for Q1 2026 at Ascendis Pharma A, up from -$189.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.6 billion in Q4 2024 to a low of -$345.8 million in Q2 2024.
• The 5-year median for Common Equity is -$79.9 million (2023), against an average of $220.7 million.
• Peak annual rise in Common Equity reached 1730.95% in 2024, while the deepest fall reached 589.79% in 2024.
• Ascendis Pharma A's Common Equity stood at $268.7 million in 2022, then plunged by 158.34% to -$156.8 million in 2023, then soared by 1730.95% to $2.6 billion in 2024, then slumped by 107.41% to -$189.5 million in 2025, then jumped by 401.42% to $571.3 million in 2026.
• The last three Common Equity figures came in at $571.3 million (Q1 2026), -$189.5 million (Q4 2025), and -$203.5 million (Q3 2025), per Business Quant data.